<- Go home

Added to YB: 2024-07-26

Pitch date: 2024-07-23

NTRA [bullish]

Natera, Inc.

+119.8%

current return

Author Info

No bio for this author

Company Info

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Market Cap

$28.2B

Pitch Price

$105.53

Price Target

N/A

Dividend

N/A

EV/EBITDA

-91.38

P/E

-89.19

EV/Sales

12.92

Sector

Biotechnology

Category

growth

Show full summary:
Voya Small Cap Growth Strategy Portfolio Holding: Natera, Inc.

NTRA: Prenatal genetic testing co. Strong Signatera volume driving revenue growth. Better-than-expected gross margins. 2024 rev growth guidance 23% (midpoint), likely conservative. Trimmed position due to high valuation despite strong performance. Remains top 3 holding.

Read full article (1 min)